Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Not Applicable:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Not Applicable
3 (100.0%)Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia
Not Applicable
Recruiting
- Conditions
- Critical Lower Limb IschemiaCritical Limb-Threatening IschemiaCritical Limb Ischemia
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- R3 Vascular Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06075940
- Locations
- 🇦🇺
Prince of Wales Hopsital, Randwick, New South Wales, Australia
Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease
Not Applicable
Recruiting
- Conditions
- Chronic Limb-Threatening Ischemia
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- R3 Vascular Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06071429
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸CUMC/NYP, New York, New York, United States
Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease
Not Applicable
Recruiting
- Conditions
- Lower Extremity ClaudicationLower Extremity IschemiaPeripheral Arterial DiseaseAtherosclerotic Lesion
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- R3 Vascular Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04912323
- Locations
- 🇦🇹
Medical University Graz, Graz, Austria
🇨🇦CRCHUM Université Montreal, Montréal, Canada
🇨🇦Hopital Saint-Francois d'Assise, Québec, Canada
News
No news found